Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Sobi to acquire Arthrosi Therapeutics, strengthening pipeline for the potential treatment of gout. Under terms, Sobi acquires Arthrosi's lead asset…
The Arthrosi acquisition gives Sobi a differentiated uricosuric asset in a gout market that remains dominated by generic xanthine oxidase inhibitors despite…
Positive topline results from the pivotal Phase 3 REDUCE 2 study of pozdeutinurad in gout (n=811). Both doses met the primary endpoint of serum urate <6 mg/dL…
Source summaries from our enrichment pipeline; follow links for originals.
All 12 sources with sentiment breakdown →
Sobi acquired Arthrosi Therapeutics for $950M upfront and up to $550M in clinical/regulatory/sales milestones (total up to $1.5B); the acquisition closed in February 2026. The deal added pozdeutinurad (AR882), a once-daily oral URAT1 inhibitor for progressive and tophaceous gout, studied in two pivotal global Phase 3 trials, REDUCE 1 and REDUCE 2. On 21 May 2026, Sobi reported positive topline results from REDUCE 2 (n=811): both doses met the primary endpoint of serum urate <6 mg/dL at month 6 (75 mg 69.2% vs 8.1% placebo, p<0.0001; 50 mg 56.6% vs 8.1%, p<0.0001), with a safety profile consistent with prior studies. REDUCE 1 is fully enrolled with data expected in H2 2026, and detailed REDUCE 2 results are slated for a scientific congress in Q4 2026. The positive first pivotal readout supports the original deal thesis of a differentiated, next-generation uricosuric for patients inadequately controlled on first-line urate-lowering therapy.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Swedish Orphan Biovitrum AB / Arthrosi Therapeutics, Inc. (this deal) | 2025 | $1.5B | — |
| Swedish Orphan Biovitrum AB / Biovitrum | 2001 | $493M | 84 |
| Swedish Orphan Biovitrum AB / AstraZeneca PLC (Synagis US rights) | 2018 | $2.3B | 80 |
| Swedish Orphan Biovitrum AB / CTI BioPharma Corp. | 2023 | $1.7B | 60 |
| Swedish Orphan Biovitrum AB / Apellis Pharmaceuticals, Inc. | 2020 | $1.0B | — |
| Horizon Pharma plc / Crealta Holdings LLC | 2015 | $510M | 87 |
| Novartis AG / Chinook Therapeutics Inc. | 2023 | $3.5B | 78 |
← Browse all deals · How we score deals
More: 2025 deals · Swedish Orphan Biovitrum AB deals · Nephrology deals